Phase I trials complete for IV busulfan
A recent phase I study conducted at Johns Hopkins Oncology Center in Baltimore shows that an intravenous form of busulfan may be more advantageous for bone marrow transplant patients than oral busulfan.
Patients taking oral busulfan are often required to take dozens of pills each day, with a wide variability in the amount of the drug actually absorbed. However, the recent study using Horsham, PA-based Sparta Pharmaceuticals' Spartaject technology for the intravenous delivery of Spartaject busulfan show promise.
The study showed that the parenteral administration of busulfan permits more consistent drug exposure and simplifies drug administration. In the study, busulfan blood levels were less variable after Spartaject busulfan than after oral busulfan.
Spartaject technology is a drug delivery system that accommodates poorly water-soluble and water-insoluble compounds by encapsulating fine particles with a fatty layer, allowing the creation of a suspension of the drug and an intravenous injection.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content